查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
到 2030 年高通量篩選市場預測：按產品、技術、應用、最終用戶和地區分類的全球分析
市場調查報告書
商品編碼
1383355

到 2030 年高通量篩選市場預測：按產品、技術、應用、最終用戶和地區分類的全球分析

High Throughput Screening Market Forecasts to 2030 - Global Analysis By Product, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2023年全球高通量篩選市場規模將達257億美元，預計2030年將達到627.5億美元，預測期內年複合成長率為13.6%。

生物技術、製藥和生命科學研究的關鍵一步是高通量篩選（HTS）。為了了解哪些化學物質具有活性或其如何影響生物系統，需要快速測試大量化學和生物分子。此外，HTS 利用自動化機器人系統在相對較短的時間內處理數千至數百萬個樣本。藥物研發在很大程度上依賴這項技術來幫助識別潛在的候選藥物、研究與生物標的的相互作用以及評估安全性和有效性。

美國國會預算辦公室公佈的資料證實，2020年全球整體製藥業研發支出近2,000億美元，而2019年為8,300萬美元。

藥物開發和藥物研發

現代藥物研發發現和開發配合措施建立在高溫超導的基礎上。製藥業不斷尋求創新藥物來治療從癌症到罕見遺傳性疾病等各種疾病。此外，可以使用 HTS 快速篩選數千種化合物，以找到有前途的候選藥物，顯著加速並降低與藥物開發過程相關的成本。

初期成本大

高溫超導技術和系統的初期成本很高。先進的檢測技術、機器人技術和高通量篩選設備的成本可能令人望而卻步，特別是對於新興企業、小型研究機構和學術機構。此外，通常需要外部資金籌措和合作研究來支付這些初期成本。

整合人工智慧和機器學習

機器學習和人工智慧（AI）的整合可能會徹底改變 HTS 程式。這些技術可以預測化合物行為，分析大型資料集並增強篩選程序。此外，透過使用人工智慧主導的演算法，可以顯著提高藥物研發的最佳化和經濟性，這些演算法可以顯著改善命中識別、先導化合物最佳化和化合物優先排序。

缺乏經濟透明度

HTS 市場可能會受到經濟衰退、景氣衰退和研究經費轉移的重大影響。由於製藥業和學術界的資金減少，高溫超導研究和開發可能會放緩，限制最尖端科技的投資和創新。此外，長期計劃可能會落空，而獲得必要資源的機會可能會因金融不穩定而受到阻礙。

COVID-19 的影響：

高通量篩檢（HTS）市場受到 COVID-19大流行的各種影響。儘管供應鏈中斷、實驗室關閉和資源缺乏最初減緩了研究和開發工作，但對快速藥物研發發現和疫苗開發的需求導致了該病毒潛在治療方法的開發大幅加速。這增加了 HTS 市場對疫苗開發、病毒生物學研究以及抗病毒化合物篩選的需求。此外，這場大流行凸顯了自動化和遠端可控高溫超導系統的重要性，它使研究人員能夠在遵守安全預防措施和社交距離的同時進行研究。

基於細胞的檢測領域預計將成為預測期內最大的領域

在高通量篩選（HTS）市場中，基於細胞的檢測佔據最大的市場佔有率。基於細胞的檢測對於藥物研發和研究非常重要，它使用活細胞來檢查對各種物質的反應。除了促進在更俱生物學相關性的背景下篩選化合物之外，它還提供了有關候選治療藥物的毒性和功效的深入資訊。此外，基於細胞的檢測是HTS市場的支柱，佔據了很大一部分市場佔有率，並且具有廣泛的應用，包括藥物篩選、毒性測試和目標識別。 HTS 在識別潛在的治療方法候選者和了解疾病背後的複雜機制方面發揮特殊作用。

藥物研發領域預計在預測期內年複合成長率最高

在高通量篩選（HTS）市場中，藥物研發領域的年複合成長率最高。對各種病理的新藥和治療方法的需求不斷成長是 HTS 市場成長的主要驅動力。藥物研發包括先導化合物的最佳化和潛在候選藥物的鑑定，主要依靠高溫超導技術進行快速有效的篩選。此外，自動化、機器人技術和資料分析的進步所帶來的藥物研發過程的簡化加速新藥的開發。

比例最高的地區：

高通量篩選（HTS）市場預計將佔據北美地區的最大佔有率。這一優勢被認為是由於對研發的大量投資，成熟的藥物研發和生物技術行業以及對尖端藥物發現和開發技術的強烈需求。頂級高溫超導設備製造商和研究機構的存在以及政府的支持措施和資金進一步增強了北美作為高溫超導市場主要企業的地位。此外，由於其強大的醫療保健系統和對精準醫療的關注，北美在 HTS 技術的使用方面處於世界領先地位。

年複合成長率最高的地區：

在高通量篩選（HTS）市場中，亞太地區的年複合成長率最高。這種快速成長的推動因素是中國和印度等國家對精準醫療的日益關注以及對生物技術和藥物研究的投資增加。由於其龐大且多樣化的患者群體以及具有成本效益的研發能力，該地區吸引了臨床試驗和藥物研發舉措。此外，不斷增加的生命科學研究和政府支持也對亞太高溫超導市場的顯著擴張發揮了關鍵作用，證實該地區是全球高溫超導市場成長的關鍵引擎。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計/預測/年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球高通量篩選市場：依產品

  • 介紹
  • 消耗品
    • 試劑和檢測試劑盒
    • 實驗室設備
  • 儀器
    • 液體處理系統
    • 檢測系統
    • 其他儀器
  • 服務
  • 軟體
  • 其他產品

第6章 全球高通量篩選市場：依技術分類

  • 介紹
  • 基於細胞的檢測
    • 2D細胞培養
    • 3D細胞培養
      • 基於支架的技術
      • 水凝膠
      • 動物源性水凝膠
      • 基質膠
      • 膠原
      • 合成水凝膠
      • 藻酸鹽/瓊脂糖
      • 惰性基質/固體支架
      • Micropatterned Surfaces
      • 無支架的技術
      • 超低結合板
      • 懸滴板
      • 其他無支架技術
    • 基於報告基因的檢測
    • 灌流細胞培養
  • 晶片實驗室技術（LOC）
  • 無標定技術
  • 超高通量篩選
  • 其他技術

第7章 全球高通量篩選市場：依應用分類

  • 介紹
  • 藥物研發
  • 生化篩檢
  • 生命科學研究
  • 其他用途

第8章 全球高通量篩選市場：依最終用戶分類

  • 介紹
  • 製藥和生物技術公司
  • 學術研究所
  • 受託研究機構（CRO）
  • 其他最終用戶

第9章 全球高通量篩選市場：依地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第10章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司簡介

  • GE Healthcare
  • Danaher Corporation
  • Agilent Technologies Inc
  • Tecan Group Ltd.
  • Corning Incorporated
  • Sigma-Aldrich Corporation
  • Charles River Laboratories International, Inc
  • Axxam SpA
  • Thermo Fisher Scientific, Inc.
  • Hamilton Company
  • Bio-Rad Laboratories, Inc
  • Merck KGaA
  • Promega Corporation
  • BioTek Instruments, Inc.
  • PerkinElmer Inc.
  • Luminex Corporation
  • Aurora Biomed Inc
  • NanoTemper Technologies GmbH
  • Beckman Coulter Inc.
  • DIANA Biotechnologies, sro
Product Code: SMRC24205

According to Stratistics MRC, the Global High Throughput Screening Market is accounted for $25.70 billion in 2023 and is expected to reach $62.75 billion by 2030 growing at a CAGR of 13.6% during the forecast period. A crucial procedure in biotechnology, pharmaceutical, and life sciences research is high-throughput screening, or HTS. In order to determine which chemicals are active or to learn more about how they affect biological systems, a vast number of chemical or biological molecules must be rapidly tested. Furthermore, HTS processes thousands, even millions, of samples in a comparatively short amount of time by utilizing automated and robotic systems. Drug discovery relies heavily on this technology, which aids in the identification of possible drug candidates, the investigation of their interactions with biological targets, and the evaluation of their safety and effectiveness.

According to the data published by the Congressional Budget Office, in 2021, it has been observed that pharmaceutical industries have spent nearly USD 200 billion on research and development in 2020 globally compared to USD 83 million in 2019.

Market Dynamics:

Driver:

Drug development and discovery

Modern drug discovery and development efforts are built on the foundation of HTS. Innovative medications are always being sought after by the pharmaceutical industry to treat a variety of illnesses, from cancer to uncommon genetic conditions. Moreover, thousands of compounds can be quickly screened with HTS to find promising drug candidates, greatly accelerating and cutting costs associated with the drug development process.

Restraint:

Large initial expenses

HTS technologies and systems require large upfront costs. For startups, smaller research organizations, and academic institutions in particular, the cost of advanced assay technologies, robotics, and high-throughput screening equipment can be prohibitive. Additionally, external funding or collaborations are frequently required to cover these upfront costs.

Opportunity:

Integration of AI and machine learning

HTS procedures could undergo a revolution if machine learning and artificial intelligence (AI) are integrated. These technologies can predict the behavior of compounds, analyze large datasets, and enhance screening procedures. Furthermore, the efficiency and financial viability of drug discovery can be greatly increased by using AI-driven algorithms to greatly improve hit identification, lead optimization, and compound prioritization.

Threat:

Lack of economic clarity

The HTS market may be significantly impacted by recessions, downturns in the economy, or shifts in research funding. HTS research and development may slow down as a result of reduced funding from both the pharmaceutical industry and academia, which would limit investment in and innovation from cutting-edge technologies. Moreover, long-term projects can be derailed, and access to necessary resources can be impeded by economic instability.

COVID-19 Impact:

The high-throughput screening (HTS) market was impacted by the COVID-19 pandemic in a number of ways. The need for quick drug discovery and vaccine development greatly accelerated the adoption of HTS technologies to screen and identify possible treatments for the virus, even though supply chain disruptions, laboratory closures, and resource shortages initially slowed down research and development activities. This led to an increase in demand for vaccine development, biological research on the virus, and screening of antiviral compounds in the HTS market. Furthermore, the pandemic highlighted the significance of automated and remote-capable HTS systems, enabling researchers to carry out their work while abiding by safety precautions and social distancing.

The Cell-based Assays segment is expected to be the largest during the forecast period

In the high-throughput screening (HTS) market, cell-based assays hold the largest market share. A vital part of drug discovery and research, cell-based assays use living cells to examine their reactions to different substances. In addition to facilitating the screening of compounds in more biologically relevant contexts, they offer insightful information about the possible toxicity and efficacy of therapeutic candidates. Moreover, cell-based assays are fundamental to the HTS market, accounting for a sizeable portion of the market share, and have a wide range of applications, such as drug screening, toxicity testing, and target identification. They play a special role in figuring out possible treatment candidates and comprehending the intricate mechanisms underlying diseases.

The Drug Discovery segment is expected to have the highest CAGR during the forecast period

In the high-throughput screening (HTS) market, drug discovery is the segment with the highest CAGR. The rising demand for novel medications and treatments across a range of disease states is a major driver of market growth for HTS. Drug discovery, which includes optimizing lead compounds and identifying possible drug candidates, mainly depends on HTS technologies for quick and effective screening. Additionally, the development of new drugs has accelerated due to the streamlining of drug discovery processes brought about by advances in automation, robotics, and data analysis.

Region with largest share:

The high-throughput screening (HTS) market is anticipated to hold the largest share in the North American region. Significant investments in research and development, a well-established pharmaceutical and biotechnology industry, and a strong need for cutting-edge drug discovery and development technologies are all considered contributing factors to this dominance. Further bolstering North America's standing as a major player in the HTS market is the existence of top HTS equipment manufacturers and research facilities, as well as supportive government initiatives and funding. Furthermore, North America leads the world in the use of HTS technologies due to the region's strong healthcare system and emphasis on precision medicine.

Region with highest CAGR:

In the high-throughput screening (HTS) market, the Asia-Pacific region is growing at the highest CAGR. The growing emphasis on precision medicine in nations like China and India, as well as increased investments in biotechnology and pharmaceutical research, are driving this rapid growth. Clinical trials and drug discovery initiatives find the region appealing due to its large and diverse patient population and cost-effective research and development capabilities. Moreover, a rise in life sciences research endeavors and government backing also play a significant role in the impressive expansion of the Asia-Pacific HTS market, securing the region's standing as a major engine of global HTS market growth.

Key players in the market

Some of the key players in High Throughput Screening market include: GE Healthcare, Danaher Corporation, Agilent Technologies Inc, Tecan Group Ltd., Corning Incorporated, Sigma-Aldrich Corporation, Charles River Laboratories International, Inc, Axxam SpA, Thermo Fisher Scientific, Inc., Hamilton Company, Bio-Rad Laboratories, Inc, Merck KGaA, Promega Corporation, BioTek Instruments, Inc., PerkinElmer Inc., Luminex Corporation , Aurora Biomed Inc, NanoTemper Technologies GmbH, Beckman Coulter Inc. and DIANA Biotechnologies, s.r.o.

Key Developments:

In October 2023, GE HealthCare announced an exclusive global licensing agreement with SOFIE Biosciences (SOFIE), a Virginia, U.S.-based Company, to develop, manufacture and commercialize SOFIE's Gallium-68 and Fluorine-18 labelled diagnostics targeting fibroblast activation protein (FAP). Financial terms were not disclosed.

In August 2023, Danaher will acquire all outstanding Abcam shares for $24 per share in cash, with a total enterprise value of approximately $5.7 billion, including Abcam's assumed debts and net of acquired cash. Danaher plans to fund the acquisition using cash on hand and proceeds from the issuance of commercial paper.

In March 2023, Agilent Technologies Inc announced a multi-year distribution agreement with Proscia® - a leader in digital pathology - to offer a comprehensive digital diagnostic pathology system. Combining Agilent's trusted pathology staining solutions with Proscia's Concentriq® Dx enterprise pathology platform will empower pathology labs to transform diagnostic efficiency and quality to improve patient health outcomes.

Products Covered:

  • Consumables
  • Instruments
  • Services
  • Software
  • Other Products

Technologies Covered:

  • Cell-based Assays
  • Lab-on-a-Chip Technology (LOC)
  • Label-free Technology
  • Ultra High Throughput Screening
  • Other Technologies

Applications Covered:

  • Drug Discovery
  • Biochemical Screening
  • Life Sciences Research
  • Other Applications

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global High Throughput Screening Market, By Product

  • 5.1 Introduction
  • 5.2 Consumables
    • 5.2.1 Reagents & Assay Kits
    • 5.2.2 Laboratory Equipment
  • 5.3 Instruments
    • 5.3.1 Liquid Handling Systems
    • 5.3.2 Detection Systems
    • 5.3.3 Other Instruments
  • 5.4 Services
  • 5.5 Software
  • 5.6 Other Products

6 Global High Throughput Screening Market, By Technology

  • 6.1 Introduction
  • 6.2 Cell-based Assays
    • 6.2.1 2D Cell Culture
    • 6.2.2 3D Cell Culture
      • 6.2.2.1 Scaffold-based Technology
      • 6.2.2.2 Hydrogels
      • 6.2.2.3 Animal-derived Hydrogels
      • 6.2.2.4 Matrigel
      • 6.2.2.5 Collagen
      • 6.2.2.6 Synthetic Hydrogels
      • 6.2.2.7 Alginate/Agarose
      • 6.2.2.8 Inert Matrix/Solid Scaffolds
      • 6.2.2.9 Micropatterned Surfaces
      • 6.2.2.10 Scaffold-free Technology
      • 6.2.2.11 Ultra-low Binding Plates
      • 6.2.2.12 Hanging-drop Plates
      • 6.2.2.13 Other Scaffold-free Technologies
    • 6.2.3 Reporter-based Assays
    • 6.2.4 Perfusion Cell Culture
  • 6.3 Lab-on-a-Chip Technology (LOC)
  • 6.4 Label-free Technology
  • 6.5 Ultra High Throughput Screening
  • 6.6 Other Technologies

7 Global High Throughput Screening Market, By Application

  • 7.1 Introduction
  • 7.2 Drug Discovery
  • 7.3 Biochemical Screening
  • 7.4 Life Sciences Research
  • 7.5 Other Applications

8 Global High Throughput Screening Market, By End User

  • 8.1 Introduction
  • 8.2 Pharmaceutical & Biotechnology Companies
  • 8.3 Academic & Research Institutes
  • 8.4 Contract Research Organizations (CROs)
  • 8.5 Other End Users

9 Global High Throughput Screening Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 GE Healthcare
  • 11.2 Danaher Corporation
  • 11.3 Agilent Technologies Inc
  • 11.4 Tecan Group Ltd.
  • 11.5 Corning Incorporated
  • 11.6 Sigma-Aldrich Corporation
  • 11.7 Charles River Laboratories International, Inc
  • 11.8 Axxam SpA
  • 11.9 Thermo Fisher Scientific, Inc.
  • 11.10 Hamilton Company
  • 11.11 Bio-Rad Laboratories, Inc
  • 11.12 Merck KGaA
  • 11.13 Promega Corporation
  • 11.14 BioTek Instruments, Inc.
  • 11.15 PerkinElmer Inc.
  • 11.16 Luminex Corporation
  • 11.17 Aurora Biomed Inc
  • 11.18 NanoTemper Technologies GmbH
  • 11.19 Beckman Coulter Inc.
  • 11.20 DIANA Biotechnologies, s.r.o.

List of Tables

  • Table 1 Global High Throughput Screening Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global High Throughput Screening Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global High Throughput Screening Market Outlook, By Consumables (2021-2030) ($MN)
  • Table 4 Global High Throughput Screening Market Outlook, By Reagents & Assay Kits (2021-2030) ($MN)
  • Table 5 Global High Throughput Screening Market Outlook, By Laboratory Equipment (2021-2030) ($MN)
  • Table 6 Global High Throughput Screening Market Outlook, By Instruments (2021-2030) ($MN)
  • Table 7 Global High Throughput Screening Market Outlook, By Liquid Handling Systems (2021-2030) ($MN)
  • Table 8 Global High Throughput Screening Market Outlook, By Detection Systems (2021-2030) ($MN)
  • Table 9 Global High Throughput Screening Market Outlook, By Other Instruments (2021-2030) ($MN)
  • Table 10 Global High Throughput Screening Market Outlook, By Services (2021-2030) ($MN)
  • Table 11 Global High Throughput Screening Market Outlook, By Software (2021-2030) ($MN)
  • Table 12 Global High Throughput Screening Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 13 Global High Throughput Screening Market Outlook, By Technology (2021-2030) ($MN)
  • Table 14 Global High Throughput Screening Market Outlook, By Cell-based Assays (2021-2030) ($MN)
  • Table 15 Global High Throughput Screening Market Outlook, By 2D Cell Culture (2021-2030) ($MN)
  • Table 16 Global High Throughput Screening Market Outlook, By 3D Cell Culture (2021-2030) ($MN)
  • Table 17 Global High Throughput Screening Market Outlook, By Reporter-based Assays (2021-2030) ($MN)
  • Table 18 Global High Throughput Screening Market Outlook, By Perfusion Cell Culture (2021-2030) ($MN)
  • Table 19 Global High Throughput Screening Market Outlook, By Lab-on-a-Chip Technology (LOC) (2021-2030) ($MN)
  • Table 20 Global High Throughput Screening Market Outlook, By Label-free Technology (2021-2030) ($MN)
  • Table 21 Global High Throughput Screening Market Outlook, By Ultra High Throughput Screening (2021-2030) ($MN)
  • Table 22 Global High Throughput Screening Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 23 Global High Throughput Screening Market Outlook, By Application (2021-2030) ($MN)
  • Table 24 Global High Throughput Screening Market Outlook, By Drug Discovery (2021-2030) ($MN)
  • Table 25 Global High Throughput Screening Market Outlook, By Biochemical Screening (2021-2030) ($MN)
  • Table 26 Global High Throughput Screening Market Outlook, By Life Sciences Research (2021-2030) ($MN)
  • Table 27 Global High Throughput Screening Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 28 Global High Throughput Screening Market Outlook, By End User (2021-2030) ($MN)
  • Table 29 Global High Throughput Screening Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 30 Global High Throughput Screening Market Outlook, By Academic & Research Institutes (2021-2030) ($MN)
  • Table 31 Global High Throughput Screening Market Outlook, By Contract Research Organizations (CROs) (2021-2030) ($MN)
  • Table 32 Global High Throughput Screening Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.